Published in Blood on May 11, 2007
Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 4.16
Sialic acids in human health and disease. Trends Mol Med (2008) 2.61
Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol (2009) 2.22
Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res (2009) 2.04
Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol (2012) 1.58
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol (2010) 1.29
The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res (2009) 1.28
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost (2011) 1.20
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood (2013) 1.19
Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol (2011) 1.18
Regulation of tumor growth and metastasis: the role of tumor microenvironment. Cancer Growth Metastasis (2014) 1.15
Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells. Br J Cancer (2009) 1.12
New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol (2009) 1.11
Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol (2009) 1.11
Platelets at the interface of thrombosis, inflammation, and cancer. Blood (2015) 1.11
Tissue factor and PAR2 signaling in the tumor microenvironment. Arterioscler Thromb Vasc Biol (2009) 1.09
Platelets and cancer: a casual or causal relationship: revisited. Cancer Metastasis Rev (2014) 1.07
NETosis: a new factor in tumor progression and cancer-associated thrombosis. Semin Thromb Hemost (2014) 1.05
Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome. Blood (2011) 1.00
Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients. Ann Fam Med (2010) 0.95
Tissue factor and cancer. Thromb Res (2012) 0.95
What do prostate cancer patients die of? Oncologist (2011) 0.95
Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer. Surg Today (2014) 0.95
Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep (2013) 0.94
Stroke and Cancer- A Complicated Relationship. J Neurol Transl Neurosci (2015) 0.93
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
Colorectal cancer and hypercoagulability. Surg Today (2013) 0.92
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med (2014) 0.91
Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond. J Mol Med (Berl) (2013) 0.90
Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management. Curr Oncol (2014) 0.88
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc (2012) 0.87
Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat Commun (2016) 0.86
Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis. PLoS One (2013) 0.86
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Pulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literature. Medicine (Baltimore) (2014) 0.83
Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution. Int J Clin Exp Med (2015) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Acute Myocardial Infarction in Association with Occult Ovarian Cancer. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2013) 0.82
Diffuse Arterial Thrombosis as a First Manifestation of Occult Malignancy. Case Rep Med (2016) 0.81
NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb Res (2016) 0.81
Pulmonary Venous Obstruction in Cancer Patients. J Oncol (2015) 0.81
Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. Front Oncol (2014) 0.81
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
The incidence and predictors of thromboembolic events in patients with lung cancer. ScientificWorldJournal (2014) 0.80
Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther (2016) 0.80
Trousseau syndrome. CMAJ (2012) 0.79
A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms. Biomacromolecules (2013) 0.79
Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour. Case Rep Vasc Med (2013) 0.79
Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol (2012) 0.79
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr (2015) 0.79
SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. Clin Exp Metastasis (2013) 0.79
Characteristics of cryptogenic stroke in cancer patients. Ann Clin Transl Neurol (2016) 0.79
Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol (2016) 0.78
Trousseau's Syndrome Caused by Intrahepatic Cholangiocarcinoma: An Autopsy Case Report and Literature Review. Case Rep Oncol (2014) 0.78
Trousseau's Syndrome, a Previously Unrecognized Condition in Acute Ischemic Stroke Associated With Myocardial Injury. J Investig Med High Impact Case Rep (2014) 0.78
Tumors, ticks and tissue factor. J Thromb Haemost (2009) 0.77
Microparticles as Biomarkers of Blood Coagulation in Cancer. Biomark Cancer (2015) 0.77
Co-occurrence of multiple cerebral infarctions due to hypercoagulability associated with malignancy and meningeal carcinomatosis as the initial manifestation of gastric cancer. BMC Neurol (2014) 0.77
Multiple embolic cerebral infarcts as the first manifestation of metastatic ovarian cancer. BMJ Case Rep (2015) 0.77
Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Cancer Prev Res (Phila) (2016) 0.76
Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets. World J Clin Oncol (2014) 0.76
NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology. Front Immunol (2016) 0.76
Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis. Oncol Lett (2012) 0.76
Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study. Springerplus (2015) 0.75
Acute Bilateral Renal and Splenic Infarctions Occurring during Chemotherapy for Lung Cancer. Intern Med (2016) 0.75
Risk factors and prognosis of pulmonary embolism in patients with lung cancer. Medicine (Baltimore) (2017) 0.75
Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6. Sci Rep (2017) 0.75
Recurrent thromboflebitis as a warning sign for cancer: a case report. Cases J (2009) 0.75
Cancer-related multiple brain infarctions caused by Trousseau syndrome in a patient with metastatic colon cancer: a case report. Surg Case Rep (2016) 0.75
Role of factor xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol (2011) 0.75
External Jugular Vein Thrombosis as a Sign of Metastatic Breast Cancer. J Breast Health (2013) (2017) 0.75
Cancer and Thrombosis: The Platelet Perspective. Front Cell Dev Biol (2017) 0.75
Unexpected outcome from Trousseau syndrome. BMC Surg (2011) 0.75
Trousseau's syndrome in a patient with advanced stage gastric cancer. World J Gastroenterol (2015) 0.75
Pulmonary embolism in non-brain tumor patients after surgery-a retrospective study in China. World J Surg Oncol (2017) 0.75
Extensive Bilateral Lemierre Syndrome due to Methicillin-Resistant Staphylococcus epidermidis in a Patient with Lung Adenocarcinoma. Tuberc Respir Dis (Seoul) (2015) 0.75
Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med (2017) 0.75
Silent pulmonary thromboembolism in neurosurgery patients: Report of 2 cases and literature review. Medicine (Baltimore) (2016) 0.75
Trousseau's Syndrome in Cholangiocarcinoma: The Risk of Making the Diagnosis. Clin Med Res (2016) 0.75
Trousseau's syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report. Oncol Lett (2016) 0.75
Trousseau syndrome presenting with penile gangrene. JAAD Case Rep (2017) 0.75
Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban. Intern Med (2017) 0.75
Blue toe syndrome and sunitinib. Int J Clin Oncol (2010) 0.75
Platelet-derived Extracellular Vesicles: An Emerging Therapeutic Approach. Int J Biol Sci (2017) 0.75
The role of mucin-educated platelet activation in tumor invasiveness: An unfolding concern in the realm of cancer biology. Biomedicine (Taipei) (2017) 0.75
Rapidly progressive symptom development of pulmonary arterial hypertension: a case report of Trousseau syndrome. Heart Vessels (2013) 0.75
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA (2005) 6.16
Molecular diversity of heparan sulfate. J Clin Invest (2001) 5.40
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 3.83
Heparin. N Engl J Med (1991) 3.66
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) (1977) 3.20
Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A (2002) 3.10
Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A (2001) 3.04
Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood (1983) 3.03
P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A (1998) 3.02
Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem (2001) 2.85
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol (2004) 2.43
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost (1999) 2.07
The structure and assembly of secreted mucins. J Biol Chem (1999) 2.00
Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest (1998) 1.97
Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost (2004) 1.91
Inflammatory roles of P-selectin. J Clin Invest (1993) 1.87
Molecular basis for the relationship between thrombosis and cancer. Thromb Res (2001) 1.84
Mucin glycoproteins in neoplasia. Glycoconj J (1996) 1.81
Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. Cancer Res (2001) 1.80
Immunohistochemical identification of tissue factor in solid tumors. Cancer (1992) 1.77
Cancer and the prothrombotic state. Lancet Oncol (2002) 1.74
The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol (2004) 1.73
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest (2003) 1.73
Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood (1993) 1.67
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Tumor shedding and coagulation. Science (1981) 1.64
A factor X-activating cysteine protease from malignant tissue. J Clin Invest (1981) 1.50
The P-selectin, tissue factor, coagulation triad. J Thromb Haemost (2005) 1.49
Order out of complexity--protein structures that interact with heparin. Curr Opin Struct Biol (2001) 1.45
Tissue factor as a tumor procoagulant. Cancer Metastasis Rev (1992) 1.44
Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol (2003) 1.41
MUC1: the polymorphic appearance of a human mucin. Glycobiology (2000) 1.39
Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost (2002) 1.39
Trousseau's syndrome. Devastating coagulopathy in the absence of heparin. Am J Med (1985) 1.38
The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature (2005) 1.37
Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol (2005) 1.35
Calcium-dependent heparin-like ligands for L-selectin in nonlymphoid endothelial cells. Science (1993) 1.34
The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med (1973) 1.30
Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol (1999) 1.29
Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb (2006) 1.27
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry (1985) 1.25
Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer (1997) 1.20
Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev (2002) 1.19
Trousseau's syndrome. West J Med (1993) 1.19
Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost (2006) 1.18
Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res (2006) 1.16
Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemost (2003) 1.16
Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res (2005) 1.14
Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups. J Biol Chem (1995) 1.08
Tumor sialomucin complexes as tumor antigens and modulators of cellular interactions and proliferation. J Cell Sci (1992) 1.07
Usefulness of novel tumour markers. Ann Oncol (1999) 1.07
Tumors, mucus production, and hypercoagulability. Ann N Y Acad Sci (1974) 1.06
Mucin-type O-glycans and leukosialin. Biochim Biophys Acta (1999) 1.04
Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? Cancer Res (2006) 1.04
The heparins and cancer: review of clinical trials and biological properties. Vasc Med (2004) 1.03
The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost (2006) 1.00
Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung. Cancer Res (1983) 0.98
Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J Cell Biochem (1996) 0.98
Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer. Cancer Res (1995) 0.96
The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol (2006) 0.96
Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature. J Clin Gastroenterol (1999) 0.95
Coagulopathies of liver disease. Clin Lab Med (1994) 0.93
Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma. Cancer Res (1990) 0.93
Circulating membrane vesicles in leukemic blood. Cancer Res (1985) 0.92
Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res (1986) 0.92
Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin. Biochemistry (1991) 0.91
Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis. Biochem J (2002) 0.91
Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer (1987) 0.89
The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis (2003) 0.88
Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis (1998) 0.87
Therapeutic equivalency of low-molecular-weight heparins. Ann Pharmacother (2002) 0.87
What else can 'Heparin' do? Haemostasis (1999) 0.87
Tissue factor on the loose. Semin Thromb Hemost (2000) 0.86
The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation. Thromb Res (2000) 0.86
Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer. Lancet (1997) 0.85
Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hematol Oncol Clin North Am (2003) 0.85
Coagulation disorders in cancer. Hematol Oncol Clin North Am (1996) 0.85
A functional role for hemostasis in early cancer development. Cancer Res (2005) 0.85
Low-molecular-weight heparin in thrombosis and cancer. Semin Thromb Hemost (2004) 0.84
Hypercoagulability preceding cancer. The iron hypothesis. J Thromb Haemost (2005) 0.84
Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol (1998) 0.83
Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor. Arch Biochem Biophys (1998) 0.83
Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2. Scand J Gastroenterol (1991) 0.82
Low-molecular-weight heparin in oncology. Anticancer Res (2003) 0.82
Non-anticoagulant effects of heparin in carcinoma metastasis and Trousseau's syndrome. Pathophysiol Haemost Thromb (2003) 0.82
Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev (2002) 0.82
Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties. Int J Cancer (1988) 0.82
Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis (2000) 0.82
Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis (2000) 0.82
Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host? J Thromb Haemost (2005) 0.81
Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome. Ann Hematol (1997) 0.81
P-selectin induction of tissue factor biosynthesis and expression. Haemostasis (1996) 0.81
Molecular interactions between heparin cofactor II and thrombin. Semin Thromb Hemost (1992) 0.81
Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome. Ann Pharmacother (1996) 0.80
Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost (2001) 0.80